Vol 3 (June 25, 2025): AME Clinical Trials Review

Treatment of newly diagnosed transplant ineligible multiple myeloma: is there a BENEFIT to adding bortezomib to the standard backbone?

COSMIC-312: lessons learned from another combination immune checkpoint and multi-kinase inhibitor trial

Nutrition following esophagectomy, what’s best?

The new kid on the block: will asciminib change frontline therapy of chronic myeloid leukemia patients?

Eradication of Helicobacter pylori and its impact on the incidence of gastric cancer

Lung cancer detection by electronic nose: ready for prime time?

Novel extended quadruplet induction regimens—challenging the need for upfront high-dose therapy in newly diagnosed all-risk multiple myeloma patients

Immunotherapy as the new standard of care for advanced endometrial cancer

Should routine dual antiplatelet therapy be recommended after elective coronary artery bypass surgery: insights from the DACAB-FE trial

Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial: the additive value of radiation therapy in the management of patients with lymphoma

Is it time to recommend dual antiplatelet therapy for all following coronary artery bypass graft surgery?—an updated review of clinical trials